Patients in the immune-tolerant phase of hepatitis B virus infection should receive antiviral therapy to reduce viral load
Main Author: | LIN Bingliang |
---|---|
Format: | Article |
Language: | zho |
Published: |
Editorial Department of Journal of Clinical Hepatology
2021-04-01
|
Series: | Linchuang Gandanbing Zazhi |
Online Access: | http://www.lcgdbzz.org/cn/article/doi/10.3969/j.issn.1001-5256.2021.04.009 |
Similar Items
-
Antiviral therapy should be used selectively in the immune-tolerant phase of hepatitis B virus infection
by: LI Letian
Published: (2021-06-01) -
Antiviral therapy should be selected for patients in the immune-tolerant phase of chronic hepatitis B virus infection
by: CHEN Xinyue
Published: (2021-06-01) -
Active antiviral therapy should be given in the immune tolerance stage of hepatitis B virus infection
by: SHANG Jia
Published: (2021-04-01) -
Patients in the immune-tolerant phase of chronic hepatitis B can receive antiviral therapy conditionally
by: XIAO Li
Published: (2021-04-01) -
Antiviral therapy is not recommended for patients in the immune-tolerant phase of hepatitis B virus infection
by: LI Minghui
Published: (2021-04-01)